Celularity (Celularity) Net Margin % : -2,479.56% (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Celularity Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Celularity's Net Income for the three months ended in Sep. 2023 was $-93.88 Mil. Celularity's Revenue for the three months ended in Sep. 2023 was $3.79 Mil. Therefore, Celularity's net margin for the quarter that ended in Sep. 2023 was -2,479.56%.

The historical rank and industry rank for Celularity's Net Margin % or its related term are showing as below:

CELU' s Net Margin % Range Over the Past 10 Years
Min: -1458.42 Med: -469.27 Max: 78.95
Current: -1226.72

CELU's Net Margin % is ranked worse than
75.22% of 1033 companies
in the Biotechnology industry
Industry Median: -156.83 vs CELU: -1226.72

Celularity Net Margin % Historical Data

The historical data trend for Celularity's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celularity Net Margin % Chart

Celularity Annual Data

Trend

Dec20

Dec21

Dec22

Net Margin %

-1,458.42

-469.27

78.95

Celularity Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Net Margin %	Get a 7-Day Free Trial									116.06	591.77	-1,626.86	-1,632.03	-2,479.56

Competitive Comparison of Celularity's Net Margin %

For the Biotechnology subindustry, Celularity's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Celularity's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celularity's Net Margin % distribution charts can be found below:

* The bar in red indicates where Celularity's Net Margin % falls into.

Celularity Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Celularity's Net Margin for the fiscal year that ended in Dec. 2022 is calculated as

Net Margin	=	Net Income (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	14.192	/	17.975
	=	78.95 %

Celularity's Net Margin for the quarter that ended in Sep. 2023 is calculated as

Net Margin	=	Net Income (Q: Sep. 2023 )	/	Revenue (Q: Sep. 2023 )
	=	-93.876	/	3.786
	=	-2,479.56 %

Celularity (NAS:CELU) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Celularity Net Margin % Related Terms

Thank you for viewing the detailed overview of Celularity's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Celularity (Celularity) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celularity Inc (NAS:CELU) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

170 Park Avenue, Florham Park, NJ, USA, 07932

Website

https://www.celularity.com

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases.

Executives

Kok Thay Lim	director	22ND FLOOR, WISMA GENTING, JALAN SULTAN ISMAIL, KUALA LUMPUR N8 50250
Robert J Hariri	director, officer: Chief Executive Officer	341 MENDHAM ROAD, BERNARDSVILLE NJ 07924
Ling Geoffrey M.d.	director	C/O CATALYST BIOSCIENCES, INC., 611 GATEWAY BOULEVARD, SUITE 710, SOUTH SAN FRANCISCO CA 94080
Berhad Genting	10 percent owner	24TH FLOOR, WISMA GENTING, JALAN SULTAN ISMAIL, KUALA LUMPUR N8 50250
Adrian Kilcoyne	officer: See Remarks	533 AIRPORT BLVD., SUITE 400, BURLINGAME CA 94010
John Sculley	director	C/O KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVENUE, LEXINGTON MA 02421
Kyle Fletcher	officer: General Counsel	CELULARITY INC., 170 PARK AVE., FLORHAM PARK NJ 07932
Peter Diamandis	director	4640 ADMIRALTY WAY, SUITE 500, MARINA DEL REY CA 90292
Dean C Kehler	director	C/O TRIMARAN CAPITAL PARTNERS, 622 THIRD AVENUE, 35TH FLOOR, NEW YORK NY 10017
Robin L Smith	director	C/O PHASE III MEDICAL, INC., 330 SOUTH SERVICE ROAD, SUITE 120, MELVILLE NY 11747
Marc Mazur	director	31 WEST 52ND ST. 17TH FLOOR, NEW YORK NY 10019
Diane L. Parks	director	29 EMMONS DRIVE, SUITE B-10, PRINCETON NJ 08540
Bradley Glover	director, officer: Chief Technology Officer	C/O CELULARITY INC., 170 PARK AVENUE, FLORHAM PARK NJ 07932
Stephen Brigido	officer: Pres, Functional Regeneration	C/O CELULARITY INC., 170 PARK AVENUE, FLORHAM PARK NJ 07932
Anne Jones	director, officer: Chief Business Officer	C/O CELULARITY INC., 170 PARK AVENUE, FLORHAM PARK NJ 07932